Our innovation begins with responsible raw material acquisition. We collaborate with seafood processing companies to source crustacean shell waste and transform it into a valuable biomaterial resource. Instead of being discarded or underutilized, this waste becomes the foundation of advanced chitosan production.

​

Through structured sourcing partnerships, we aim to create a circular supply chain that benefits both processors and high-value biomaterial industries. Consistent raw material quality and supply continuity are critical to achieving medical- and pharmaceutical-grade standards.

​

​

​

The second step of our innovation platform focuses on controlled chitosan extraction and refinement. We develop optimized deacetylation processes, purification protocols, and material control systems to produce high-purity chitosan tailored for regulated industries.

​

Our approach emphasizes:

• Degree of deacetylation control

• Molecular weight optimization

• Batch-to-batch reproducibility

• Application-driven customization

This stage transforms raw biological waste into a high-value functional biopolymer ready for medical, pharmaceutical, cosmetic, veterinary, and advanced material applications.

​

The final stage of our platform converts chitosan and complementary biopolymers into functional bioplastic systems engineered for performance. We develop antimicrobial films, biodegradable material blends, and application-specific formulations designed for regulated and high-value sectors.

​

By combining material science with formulation engineering, we deliver bio-based alternatives that offer antimicrobial functionality, biocompatibility, and environmental sustainability — without sacrificing mechanical performance or industrial scalability.

​

This step completes the circular transformation from waste to advanced biomaterial solution.